Akmez Latona: Clauss vs PT-Derived Fibrinogen in Relation to Viscoelastic Clot Strength
Akmez Latona, Specialist Emergency Physician at Queensland Health, reposted from RPTH Journal on LinkedIn:
”Coagulation profiles in Queensland Health report two fibrinogen measures: Clauss and PT-derived.
A novel aspect we introduced is the comparison of Clauss and PT-derived fibrinogen with viscoelastic clot firmness (ROTEM FIBTEM A5) across different domains of coagulopathy.
The findings show these tests are not interchangeable in context of low clot firmness and inform recommendations for fibrinogen reporting in critical bleeding within laboratory workflows.
Thank you Emergency Medicine Foundation – Australasia (EMF) for funding this study!”
RPTH Journal shared on LinkedIn about a recent article by Akmez Latona et al, adding:
”Fibrinogen testing in critical bleeding: Clauss or PT-derived, does it matter?
Two common assays are used to measure Fibrinogen: the Clauss method (Fib-C), considered the laboratory gold standard, and the prothrombin time-derived assay (Fib-D), a faster and cheaper alternative.
But are they interchangeable?
A new study in RPTH Journal compared both methods against viscoelastic clot firmness (ROTEM FIBTEM-A5) across all Queensland Health hospitals, using over 2,200 paired results from 2019 to 2025.
Key findings:
- Fib-C correlated more strongly with FIBTEM-A5 than Fib-D
- Fib-C showed higher accuracy for detecting critically low clot firmness
- Fib-D systematically overestimated fibrinogen levels compared with Fib-C – in trauma, chronic liver disease, and overall
The clinical implication is clear: in critical bleeding, Fib-C better reflects true clot firmness, and routine Fib-D reporting may be misleading rather than helpful.”
Title: Diagnostic accuracy of Clauss and prothrombin time–derived fibrinogen against rotational thromboelastometry FIBTEM-A5
Authors: Akmez Latona, Kate Hill, Mark Rane, Alan Ho, Biswadev Mitra
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?